Browsing Category

TRENDING NEWS

Articles Design Employee Fashion Featured News Infographics Lifestyle

The Future Of HR? It’s Getting Back Into The People Business

admin Nov 24, 2022 0

I often get asked what are the big trends I see today in HR, and I found myself getting asked that question a lot…

Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined

2026-10-24T14:00:00Z

Results include a US client who lost 145kg without surgery and a man who lost more than 80kg after being called a lost cause

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

2026-10-24T13:01:53Z

BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide...

Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress

2026-10-24T12:45:00Z

RADNOR, Pa., and SOUTH SAN FRANCISCO, Calif., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS-driven cancers,...

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

2026-10-24T12:45:00Z

CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable...

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

2026-10-24T11:00:00Z

Data presented at the 2026 Congress of the European Society for Medical Oncology

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

2026-10-24T11:00:00Z

Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026

KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination

2026-10-24T09:00:00Z

RIYADH, Saudi Arabia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is widening patients’ access to emergency expertise beyond its physical departments. Its virtual...

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

2026-10-24T08:15:00Z

BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the publication...

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

2026-10-24T08:15:00Z

Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

2026-10-24T06:35:00Z

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

2026-10-24T06:30:00Z

Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

2026-10-24T06:30:00Z

VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,...

Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

2026-10-24T03:30:32Z

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

2026-10-24T00:00:00Z

ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of...

J-Star Holding Co., Ltd. Files Interim Financial Report on Form 6-K

2026-10-23T20:15:00Z

Company is Highlighting Strategic Focus on U.S. Opportunities, Balance Sheet Improvement, and Management Commitment

The Ensign Group Schedules Third Quarter 2026 Earnings Call for Wednesday, October 28, 2026

2026-10-23T20:01:00Z

SAN JUAN CAPISTRANO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled...

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

2026-10-23T20:01:00Z

>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

2026-10-23T20:01:00Z

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

2026-10-23T20:00:00Z

NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,...

Vault Consulting Announces Nonprofit Human Resources Consulting

Mercans Introduces Revolutionary AI-Powered Time Evaluation Engine for Global Payroll

AI and Agile Practices Are Redefining HR. The Future is Already Here

International HR Day 2025: Embracing the Future of Work with…

TRENDING NEWS

The Future Of HR? It’s Getting Back Into The People Business